Parsaclisib Explained

Atc Prefix:L01
Atc Suffix:EM05
Cas Number:1426698-88-5
Pubchem:86677874
Drugbank:DB14867
Chemspiderid:64835232
Unii:OS7097575K
Kegg:D11437
Chembl:4297615
Iupac Name:4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one
C:20
H:22
Cl:1
F:1
N:6
O:2
Stdinchi:InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1
Stdinchikey:ZQPDJCIXJHUERQ-QWRGUYRKSA-N
Smiles:CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4

Parsaclisib is an investigational drug that it being evaluated for the treatment of B-cell malignancies. It is a PI3Kδ (phosphoinositide 3-kinase) inhibitor.[1] [2]

Notes and References

  1. Gerds AT, Bartalucci N, Assad A, Yacoub A . Targeting the PI3K pathway in myeloproliferative neoplasms . Expert Review of Anticancer Therapy . 22 . 8 . 835–843 . August 2022 . 35763287 . 10.1080/14737140.2022.2093192 . free . 2158/1351132 . free .
  2. Web site: Parsaclisib - Incyte Corporation . AdisInsight . Springer Nature Switzerland AG .